First quarter 2026 total revenue was
Company reaffirms 2026 revenue guidance of
“We had a great start to 2026,” said
Corporate and Financial Updates
- First quarter 2026 total revenue of
$11.1 million , up 13% compared to$9.8 million for the first quarter 2025 - Total cash and short-term investments were
$17.8 million and total borrowings were$13.2 million at the end of the first quarter 2026
Revenue for the First Quarter 2026
| For the Three Months Ended | ||||||||
| (Dollars in thousands) | 2026 | 2025 | ||||||
| Lab Essentials | $ | 8,395 | $ | 8,117 | ||||
| 2,145 | 1,162 | |||||||
| Other | 537 | 516 | ||||||
| Total revenue | $ | 11,077 | $ | 9,795 | ||||
First Quarter 2026 Financial Results
Total revenue for the first quarter 2026 was
Gross profit for the first quarter 2026 was
Operating expenses for the first quarter 2026 were
Net loss for the first quarter 2026 was
Cash used in operating activities for the first quarter 2026 was
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Reaffirms 2026 Outlook
Teknova reaffirms its fiscal 2026 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of
Upcoming Investor Conference Attendance
Conference Call and Webcast
Teknova will host a webcast and conference call on
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with
Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in
Investor Contact
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 11,077 | $ | 9,795 | ||||
| Cost of sales | 7,293 | 6,788 | ||||||
| Gross profit | 3,784 | 3,007 | ||||||
| Operating expenses: | ||||||||
| Research and development | 609 | 552 | ||||||
| Sales and marketing | 2,128 | 1,640 | ||||||
| General and administrative | 5,058 | 5,492 | ||||||
| Amortization of intangible assets | 287 | 287 | ||||||
| Total operating expenses | 8,082 | 7,971 | ||||||
| Loss from operations | (4,298 | ) | (4,964 | ) | ||||
| Other (expenses) income, net | ||||||||
| Interest expense, net | (219 | ) | (144 | ) | ||||
| Other adjustment to loan exit fee | — | 485 | ||||||
| Other income | 9 | — | ||||||
| Total other (expenses) income, net | (210 | ) | 341 | |||||
| Loss before income taxes | (4,508 | ) | (4,623 | ) | ||||
| Provision for income taxes | 47 | 22 | ||||||
| Net loss | $ | (4,555 | ) | $ | (4,645 | ) | ||
| Net loss per share—basic and diluted | $ | (0.08 | ) | $ | (0.09 | ) | ||
| Weighted average shares used in computing net loss per share—basic and diluted | 53,606,278 | 53,421,533 | ||||||
Condensed Balance Sheets (Unaudited) (In thousands) | ||||||||
| As of | As of | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,306 | $ | 5,912 | ||||
| Short-term investments, held -to-maturity | 13,478 | 15,426 | ||||||
| Accounts receivable, net | 5,672 | 4,618 | ||||||
| Inventories, net | 6,874 | 7,054 | ||||||
| Prepaid expenses and other current assets | 1,344 | 1,501 | ||||||
| Total current assets | 31,674 | 34,511 | ||||||
| Property, plant, and equipment, net | 40,524 | 41,733 | ||||||
| Operating right-of-use lease assets | 13,608 | 14,112 | ||||||
| Intangible assets, net | 11,656 | 11,943 | ||||||
| Other non-current assets | 1,195 | 1,285 | ||||||
| Total assets | $ | 98,657 | $ | 103,584 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,618 | $ | 1,378 | ||||
| Accrued liabilities | 3,363 | 4,283 | ||||||
| Current portion of operating lease liabilities | 1,915 | 1,876 | ||||||
| Total current liabilities | 6,896 | 7,537 | ||||||
| Deferred tax liabilities | 925 | 879 | ||||||
| Long-term debt, net | 13,170 | 13,123 | ||||||
| Long-term operating lease liabilities | 12,742 | 13,270 | ||||||
| Total liabilities | 33,733 | 34,809 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | 1 | ||||||
| Additional paid-in capital | 205,268 | 204,564 | ||||||
| Accumulated deficit | (140,345 | ) | (135,790 | ) | ||||
| Total stockholders’ equity | 64,924 | 68,775 | ||||||
| Total liabilities and stockholders’ equity | $ | 98,657 | $ | 103,584 | ||||
Condensed Statements of Cash Flows (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Operating activities: | ||||||||
| Net loss | $ | (4,555 | ) | $ | (4,645 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Bad debt expense | 7 | 45 | ||||||
| Inventory reserve | 413 | 437 | ||||||
| Depreciation and amortization | 1,576 | 1,580 | ||||||
| Stock-based compensation | 695 | 852 | ||||||
| Deferred taxes | 46 | 21 | ||||||
| Accrued interest income on short-term investments | (27 | ) | (54 | ) | ||||
| Amortization of discount on short-term investments | (87 | ) | (184 | ) | ||||
| Amortization of debt financing costs | 47 | 86 | ||||||
| Other adjustment to loan exit fee | — | (485 | ) | |||||
| Non-cash lease expense | 15 | 30 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,061 | ) | (1,349 | ) | ||||
| Inventories | (233 | ) | (209 | ) | ||||
| Prepaid expenses and other current assets | 157 | (4 | ) | |||||
| Other non-current assets | 90 | 63 | ||||||
| Accounts payable | 330 | 740 | ||||||
| Accrued liabilities | (772 | ) | (1,017 | ) | ||||
| Other | — | (10 | ) | |||||
| Cash used in operating activities | (3,359 | ) | (4,103 | ) | ||||
| Investing activities: | ||||||||
| Purchases of short-term investments | (3,938 | ) | (1,970 | ) | ||||
| Maturities of short-term investments | 6,000 | 6,000 | ||||||
| Purchases of property, plant, and equipment | (221 | ) | (206 | ) | ||||
| Cash provided by investing activities | 1,841 | 3,824 | ||||||
| Financing activities: | ||||||||
| Proceeds from long-term debt | — | 1,110 | ||||||
| Payment of exit fee costs | — | (1,110 | ) | |||||
| Repayment of financed insurance premiums | (97 | ) | (56 | ) | ||||
| Proceeds from exercise of stock options | 9 | 4 | ||||||
| Cash used in financing activities | (88 | ) | (52 | ) | ||||
| Change in cash and cash equivalents | (1,606 | ) | (331 | ) | ||||
| Cash and cash equivalents at beginning of period | 5,912 | 3,708 | ||||||
| Cash and cash equivalents at end of period | $ | 4,306 | $ | 3,377 | ||||
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Net loss – as reported | $ | (4,555 | ) | $ | (4,645 | ) | ||
| Add back: | ||||||||
| Interest expense, net | (219 | ) | (144 | ) | ||||
| Provision for income taxes | 47 | 22 | ||||||
| Depreciation expense | 1,289 | 1,293 | ||||||
| Amortization of intangible assets | 287 | 287 | ||||||
| EBITDA | $ | (2,713 | ) | $ | (2,899 | ) | ||
| Other and non-recurring expenses: | ||||||||
| Stock-based compensation expense | 695 | 852 | ||||||
| Other adjustment to loan exit fee | — | (485 | ) | |||||
| Adjusted EBITDA | $ | (2,018 | ) | $ | (2,532 | ) | ||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Cash used in operating activities | $ | (3,359 | ) | $ | (4,103 | ) | ||
| Purchases of property, plant, and equipment | (221 | ) | (206 | ) | ||||
| Free Cash Flow | $ | (3,580 | ) | $ | (4,309 | ) | ||
